



**CORRECTION**

# Author Correction: Cobrotoxin could be an effective therapeutic for COVID-19

Fang Lin<sup>1</sup>, Paul F. Reid<sup>2</sup> and Zheng-hong Qin<sup>1</sup>

*Acta Pharmacologica Sinica* (2020) 41:1621; <https://doi.org/10.1038/s41401-020-00533-z>

Correction to: *Acta Pharmacol Sin* <https://doi.org/10.1038/s41401-020-00501-7>, published online 25 August 2020

The authors apologize that they did not declare competing interest in the original article.

**Competing interests:** PFR, PhD, is a stakeholder in Maitland Pharma, a US company that in-licenses and manufactures therapeutic products from snake venom, but not cobrotoxin. PFR also holds several issued patents and patents pending in relation to the therapeutic use of snake venoms. The other authors declare that they have no competing interest.

<sup>1</sup>Department of Pharmacology, Laboratory of Aging and Nervous Diseases (SZS0703), College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China and

<sup>2</sup>Maitland Pharma, Orlando, FL, USA

Correspondence: Zheng-hong Qin ([qinzhenhong@suda.edu.cn](mailto:qinzhenhong@suda.edu.cn))

Published online: 18 September 2020